BRPI0507960A - métodos terapêuticos empregando precursores de óxido nìtrico - Google Patents

métodos terapêuticos empregando precursores de óxido nìtrico

Info

Publication number
BRPI0507960A
BRPI0507960A BRPI0507960-8A BRPI0507960A BRPI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A
Authority
BR
Brazil
Prior art keywords
carbamyl phosphate
nitric oxide
therapeutic methods
oxide precursors
methods employing
Prior art date
Application number
BRPI0507960-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Marshall L Summar
Brian Christman
Frederick E Barr
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BRPI0507960A publication Critical patent/BRPI0507960A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0507960-8A 2004-02-24 2005-02-24 métodos terapêuticos empregando precursores de óxido nìtrico BRPI0507960A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/785,374 US9486429B2 (en) 1999-06-01 2004-02-24 Therapeutic methods employing nitric oxide precursors
PCT/US2005/006081 WO2005082042A2 (en) 2004-02-24 2005-02-24 Therapeutic methods employing nitric oxide precursors

Publications (1)

Publication Number Publication Date
BRPI0507960A true BRPI0507960A (pt) 2007-07-17

Family

ID=34911448

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507960-8A BRPI0507960A (pt) 2004-02-24 2005-02-24 métodos terapêuticos empregando precursores de óxido nìtrico

Country Status (9)

Country Link
US (2) US9486429B2 (https=)
EP (3) EP1718289A4 (https=)
JP (5) JP2007524695A (https=)
CN (1) CN1946388B (https=)
AU (2) AU2005216270A1 (https=)
BR (1) BRPI0507960A (https=)
IL (4) IL177224A (https=)
WO (1) WO2005082042A2 (https=)
ZA (2) ZA200606575B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
DE102006021406B4 (de) * 2006-05-08 2008-08-07 B.R.A.H.M.S Aktiengesellschaft In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung
FR2907011B1 (fr) * 2006-10-17 2010-05-14 Univ Paris Descartes Utilisation de la citrulline pour le traitement des etats de denutrition
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
CN101969974A (zh) 2008-01-31 2011-02-09 范德比尔特大学 对于肺部病症的治疗
AU2014204490B2 (en) * 2008-01-31 2016-05-12 Vanderbilt University Therapeutic treatment for lung condtions
WO2009099999A2 (en) * 2008-01-31 2009-08-13 Vanderbilt University Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
WO2011051742A1 (en) * 2009-10-28 2011-05-05 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
US9572848B1 (en) 2014-03-26 2017-02-21 Aemes Research L.L.L.P. Composition of matter for sexual dysfunction
WO2017004233A1 (en) 2015-06-29 2017-01-05 Vanderbilt University Intravenous administration of citrulline during surgery
US10265286B2 (en) * 2016-12-28 2019-04-23 Vanderbilt University Sequelae of cardiopulmonary bypass-induced pulmonary injury
JP2018114414A (ja) * 2018-05-07 2018-07-26 株式会社大一商会 遊技機
US20220160846A1 (en) * 2019-02-27 2022-05-26 The Regents Of The University Of Michigan Carbamoyl phosphate synthatase-1 for the treatment and prevention of internal tissue injury
KR102951493B1 (ko) 2019-06-05 2026-04-13 아스클레피온 파마슈티칼즈, 엘엘씨 시트룰린의 개선된 합성 및 정제 방법
US12064409B2 (en) 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
US20230404956A1 (en) * 2022-06-21 2023-12-21 Asklepion Pharmaceuticals Llc Therapeutic window for citrulline therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1005A (en) * 1838-11-12 Ing and heating booms and other apabtments beqtjibing abtrficial
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NL8102724A (nl) 1980-07-11 1982-02-01 Stamicarbon Werkwijze voor de bereiding van copolymeren van etheen met tenminste een ander 1-alkeen.
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5573933A (en) * 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4996236A (en) * 1988-06-22 1991-02-26 Takeda Chemical Industries, Ltd. Therapeutic composition for hepatic encephalopathy
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
EP0560932B1 (en) * 1990-12-04 1996-09-04 The Board Of Regents, The University Of Texas System Methods and compositions for the suppression of neu mediated transformation
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
US5550316A (en) * 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US5550024A (en) * 1991-04-19 1996-08-27 Biotechnology Research & Development Corporation Genetic markers for pig litter size
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
AU6232794A (en) 1993-01-29 1994-08-15 Brigham And Women's Hospital The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5648061A (en) * 1995-05-24 1997-07-15 Thomas Jefferson University In vivo and in vitro model of cutaneous photoaging
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6796966B2 (en) * 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
WO1999018949A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6182295B1 (en) * 1999-06-14 2001-02-06 Kevin Sciglia Hat
CN1166339C (zh) * 1999-11-15 2004-09-15 Lg电子株式会社 旋风真空吸尘器中的用于集尘箱的联结装置
JP3506114B2 (ja) 2000-01-25 2004-03-15 株式会社ニコン モニタ装置及びこのモニタ装置を具えた研磨装置及び研磨方法
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US7198912B2 (en) * 2001-09-07 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
SI1841458T1 (sl) * 2005-01-06 2012-04-30 Discovery Lab Inc Zdravljenje s predpisanim odmerjanjem surfaktanta za zdravljenje ali preprečevanje bronhopulmonalne displazije
US20070184554A1 (en) * 2005-12-01 2007-08-09 Nps Allelix Corp. Biomarker of improved intestinal function
CN101969974A (zh) * 2008-01-31 2011-02-09 范德比尔特大学 对于肺部病症的治疗
WO2009099999A2 (en) * 2008-01-31 2009-08-13 Vanderbilt University Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage

Also Published As

Publication number Publication date
IL225911A (en) 2015-05-31
EP3351241A1 (en) 2018-07-25
ZA200806276B (en) 2012-12-27
JP2007524695A (ja) 2007-08-30
US20170119715A1 (en) 2017-05-04
JP6239571B2 (ja) 2017-11-29
WO2005082042A2 (en) 2005-09-09
IL225912A0 (en) 2013-06-27
JP2016074709A (ja) 2016-05-12
IL225912A (en) 2015-07-30
IL225911A0 (en) 2013-06-27
CN1946388A (zh) 2007-04-11
JP2013040176A (ja) 2013-02-28
EP2319507A1 (en) 2011-05-11
US9486429B2 (en) 2016-11-08
AU2009203177B2 (en) 2012-03-22
AU2005216270A1 (en) 2005-09-09
JP2015007090A (ja) 2015-01-15
CN1946388B (zh) 2012-03-07
ZA200606575B (en) 2012-10-31
EP1718289A2 (en) 2006-11-08
JP2018024665A (ja) 2018-02-15
EP1718289A4 (en) 2007-04-11
WO2005082042A3 (en) 2006-05-04
JP6395912B2 (ja) 2018-09-26
IL232265A0 (en) 2014-06-30
AU2009203177A1 (en) 2009-08-20
IL177224A0 (en) 2006-12-10
US20040235953A1 (en) 2004-11-25
IL177224A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
BRPI0507960A (pt) métodos terapêuticos empregando precursores de óxido nìtrico
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
WO2006135684A3 (en) Methods and kits for sense rna synthesis
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
Sharif-Zak et al. CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
NZ543467A (en) The severe acute respiratory syndrome coronavirus
WO2009106819A3 (en) Biological materials and uses thereof
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2005032495A8 (en) Gene expression profiles and methods of use
ATE494588T1 (de) Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit
WO2007133682A3 (en) 100% sequence identity detection methods for variable genomes
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
WO2008019052A3 (en) Methods and compositions for identifying biomarkers
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
ATE533501T1 (de) Verwendung des ped-faktors zur induktion von zellregenerierung
Zhao et al. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms
Baichurina et al. The study of cerebrospinal fluid microRNAs in spinal cord injury and neurodegenerative diseases: methodological problems and possible solutions
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007058968A3 (en) Gene expression profiles and methods of use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL